Xenetic Biosciences, Inc.
XBIOW
NASDAQ Capital Market17.54
USD
-5.40
- -
Xenetic Biosciences, Inc.
XBIOW
(NASDAQ Capital Market)
Recent
price
17.54
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Xenetic Biosciences, Inc. (NASDAQ:XBIO) is a clinical-stage biopharmaceutical company that develops innovative immuno-oncology technologies targeting difficult-to-treat cancers, including pancreatic carcinoma and other locally advanced or metastatic solid tumors. The company utilizes its proprietary DNase platform to enhance the efficacy of existing treatments such as immunotherapies, chemotherapy, and CAR-T therapies by degrading neutrophil extracellular traps (NETs) that contribute to cancer progression, metastasis, and treatment resistance; it also leverages the PolyXen drug delivery platform, which employs polysialic acid to extend the half-life of biologic drugs including ErepoXen (a polysialylated erythropoietin for anemia in chronic kidney disease), OncoHist (a DOT1L inhibitor for refractory acute myeloid leukemia), and other protein/peptide therapeutics. Xenetic maintains collaboration agreements with partners including Takeda Pharmaceutical Co. Ltd. for sublicensing royalties, Serum Institute of India Limited and PJSC Pharmsynthez for ErepoXen development, Belgian Volition SARL for NETs-targeted adoptive cell therapies, PeriNess for clinical trial services in Israel involving DNase as an adjunctive therapy, and Scripps Research for ongoing R&D on the DNase platform. Founded in 1996 and headquartered in Framingham, Massachusetts, the company operates primarily in the United States with global partnerships and generates revenue from royalties while advancing its pipeline toward Phase 1 trials. Recent developments include the completion of preclinical proof-of-concept studies for systemic DNase I in combination therapies across solid tumor models, advancement to mechanism-of-action and translational research ahead of an IND submission, execution of an October 2025 underwritten public offering yielding net proceeds of $3.9 million to extend its cash runway, a Q3 2025 net loss of $0.5 million amid heightened R&D spending on manufacturing and preclinical efforts, and an extension of its R&D collaboration with Scripps Research Institute.